Graphite Bio, Inc. - GRPH STOCK NEWS

Graphite Bio (Nasdaq: GRPH), a leader in gene editing, announced its participation in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Sept. 13, 2022, at 12:55 pm ET. The discussion will be broadcast live on the company’s website, with a replay available afterward. Graphite Bio is focused on developing innovative gene therapies utilizing its UltraHDR™ platform, which aims to enhance precision gene repair and potentially cure severe diseases by correcting genetic mutations.

Graphite Bio (Nasdaq: GRPH) announced significant advancements in gene editing therapies in its recent press release. The company dosed the first patient in the Phase 1/2 CEDAR trial for its investigational therapy, nulabeglogene autogedtemcel (nula-cel), aimed at treating sickle cell disease. Initial proof-of-concept data is expected by mid-2023. The company presented positive preclinical data for GPH102, its beta-thalassemia therapy, at the ASGCT Annual Meeting. As of June 30, 2022, Graphite Bio reported $328.3 million in cash, supporting its operations into Q4 2024.

Graphite Bio has commenced dosing the first patient in its Phase 1/2 CEDAR trial with GPH101, now known as nulabeglogene autogedtemcel (nula-cel), aimed at treating sickle cell disease (SCD). Nula-cel is designed to correct the genetic mutation causing SCD, offering potential as a definitive cure. Initial proof-of-concept data is expected to be released in mid-2023. The trial is open-label and will assess safety and efficacy in about 15 patients. The FDA has granted Fast Track and Orphan Drug designations for this investigational therapy, which is pivotal for the SCD community.

Graphite Bio, Inc. (NASDAQ: GRPH), a clinical-stage gene editing company, announced that its management will present at the Jefferies Healthcare Conference on June 8, 2022, at 4 p.m. ET. The presentation will be accessible via a live webcast on Graphite Bio's website. The company focuses on next-generation precision gene repair technology, aiming to treat serious diseases through its UltraHDR™ platform, which allows for precise genetic modifications. Co-founded by experts in gene therapy, Graphite Bio strives to revolutionize treatments by accurately modifying genes.

Graphite Bio presented promising preclinical data for GPH102, aimed at treating beta-thalassemia, at the ASGCT Annual Meeting. GPH102 focuses on replacing the mutated beta-globin gene to restore hemoglobin levels. The company's UltraHDR™ platform showed up to 40% homology directed repair rates in sickle cell hemopoietic stem cells. A Phase 1/2 CEDAR trial for GPH101, targeting sickle cell disease, is also ongoing. The company plans to submit an Investigational New Drug Application for GPH102 by mid-2024, pending regulatory feedback.

Graphite Bio (Nasdaq: GRPH) announced significant clinical advancements, including FDA Fast Track Designation for GPH101, a therapy for sickle cell disease. The initial patient dosing in the Phase 1/2 CEDAR trial is expected in late 2022, with proof-of-concept data anticipated in 2023. The company also plans to present new findings for GPH102 for beta-thalassemia at the upcoming ASGCT Meeting. As of March 31, 2022, Graphite holds $352.1 million in cash, ensuring operational funding into Q4 2024.

Graphite Bio (NASDAQ: GRPH), a pioneering clinical-stage gene editing company, announced its management team will participate in three upcoming investor conferences. These include the BofA Securities Healthcare Conference on May 11, 2022, the RBC Capital Markets Global Healthcare Conference on May 18, 2022, and the UBS Global Healthcare Conference on May 23, 2022. The chats will be webcast live on Graphite Bio’s website, with replays available post-event. Graphite Bio focuses on high-efficiency precision gene repair for developing therapies to address serious diseases.

Graphite Bio (NASDAQ: GRPH) announced that the FDA granted Fast Track Designation for their gene-edited therapy GPH101, targeting sickle cell disease (SCD). This investigational therapy aims to correct the genetic mutation causing SCD, representing a promising one-time treatment. The designation supports the urgent need for effective treatments for this life-threatening condition and may expedite the development process. The company expects to dose its first patient in the ongoing CEDAR trial later this year, with initial data anticipated next year.

Graphite Bio (Nasdaq: GRPH) announced the acceptance of two abstracts for presentation at the ASGCT 25th Annual Meeting from May 16-19 in Washington, D.C. The abstracts focus on GPH101, a gene therapy for sickle cell disease, and GPH102, targeting beta-thalassemia. CEO Josh Lehrer emphasized the potential of GPH102 to provide definitive cures. Presentations will include preclinical data on GPH102 and advancements from the ongoing CEDAR trial for GPH101.